TKI Hikes Survival in Recurrent Ovarian Cancer

Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013.

Source: Medscape Pathology and Laboratory Medicine Podcast - October 4, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts